Neuer Wirkstoff Daraxonrasib, ein ein oraler RAS(ON) multiselektiver Tri-Komplex-Inhibitor des aktiven Guanonintriphosphat-gebundenen Zustands des mutierten und wildtypischen RAS-Syndroms, kann Überlebenszeit bei Pankreaskarzinom verdoppeln
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | NEJM
Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, w...
www.nejm.org
June 1, 2026 at 12:46 PM
Neuer Wirkstoff Daraxonrasib, ein ein oraler RAS(ON) multiselektiver Tri-Komplex-Inhibitor des aktiven Guanonintriphosphat-gebundenen Zustands des mutierten und wildtypischen RAS-Syndroms, kann Überlebenszeit bei Pankreaskarzinom verdoppeln
#Medsky🧪 #Oncosky #pharmsky #publichealth #Pancreaticductaladenocarcinoma is a highly aggressive malignancy with a dismal prognosis. It is projected to become 2nd leading cause of cancer-related deaths by 2030 . Metastatic PDAC (mPDAC) is particularly lethal, with a 5-year survival rate of only 3%.
October 8, 2025 at 7:43 AM
#Medsky🧪 #Oncosky #pharmsky #publichealth #Pancreaticductaladenocarcinoma is a highly aggressive malignancy with a dismal prognosis. It is projected to become 2nd leading cause of cancer-related deaths by 2030 . Metastatic PDAC (mPDAC) is particularly lethal, with a 5-year survival rate of only 3%.
My mind is blown. This an earth shattering (in a good way) result that will have enormous impact for patients, caregivers, and the entire field.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | NEJM
Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, w...
www.nejm.org
June 1, 2026 at 8:37 PM
My mind is blown. This an earth shattering (in a good way) result that will have enormous impact for patients, caregivers, and the entire field.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Technical article
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | NEJM
Current therapies offer limited benefit for patients with previously treated metastatic
pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is
the key driver of PDAC, w...
share.google
June 7, 2026 at 12:14 AM
Technical article
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Read the Phase 2 Study: Biomarker Analysis from Patients with mPDAC Treated with TGFβ Antibody NIS793 (NCT04390763), in Clinical Cancer Research. buff.ly/8K6AIGz
September 27, 2026 at 10:01 PM
Read the Phase 2 Study: Biomarker Analysis from Patients with mPDAC Treated with TGFβ Antibody NIS793 (NCT04390763), in Clinical Cancer Research. buff.ly/8K6AIGz
Well that's a lovely little mic-drop of a paper: www.nejm.org/doi/full/10....
tl;dr this new drug doubles pancreatic cancer survival time. That's still not a very high number, but ...*doubles*.
tl;dr this new drug doubles pancreatic cancer survival time. That's still not a very high number, but ...*doubles*.
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | NEJM
Current therapies offer limited benefit for patients with previously treated metastatic
pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is
the key driver of PDAC, w...
www.nejm.org
August 17, 2026 at 10:33 AM
Well that's a lovely little mic-drop of a paper: www.nejm.org/doi/full/10....
tl;dr this new drug doubles pancreatic cancer survival time. That's still not a very high number, but ...*doubles*.
tl;dr this new drug doubles pancreatic cancer survival time. That's still not a very high number, but ...*doubles*.
#GI25 @ascocancer.bsky.social
Other trials in #PancreaticCancer:
1⃣Dr. Liu🗣️aPh1b trial of FG-M108 in CLDN18.2+ PDAC, Abs 729, Post#H17
2⃣ Eileen O'Reilly🗣️the CD40 agonist, mitaz+FFX for mPDAC, Abs 723; Post#H11
3⃣Dr. Seufferlein🗣️the GOBLET study: pelareorep+FFX+atezo in mPDAC, Abs 730; Post#H18
Other trials in #PancreaticCancer:
1⃣Dr. Liu🗣️aPh1b trial of FG-M108 in CLDN18.2+ PDAC, Abs 729, Post#H17
2⃣ Eileen O'Reilly🗣️the CD40 agonist, mitaz+FFX for mPDAC, Abs 723; Post#H11
3⃣Dr. Seufferlein🗣️the GOBLET study: pelareorep+FFX+atezo in mPDAC, Abs 730; Post#H18
January 11, 2025 at 6:54 PM
#GI25 @ascocancer.bsky.social
Other trials in #PancreaticCancer:
1⃣Dr. Liu🗣️aPh1b trial of FG-M108 in CLDN18.2+ PDAC, Abs 729, Post#H17
2⃣ Eileen O'Reilly🗣️the CD40 agonist, mitaz+FFX for mPDAC, Abs 723; Post#H11
3⃣Dr. Seufferlein🗣️the GOBLET study: pelareorep+FFX+atezo in mPDAC, Abs 730; Post#H18
Other trials in #PancreaticCancer:
1⃣Dr. Liu🗣️aPh1b trial of FG-M108 in CLDN18.2+ PDAC, Abs 729, Post#H17
2⃣ Eileen O'Reilly🗣️the CD40 agonist, mitaz+FFX for mPDAC, Abs 723; Post#H11
3⃣Dr. Seufferlein🗣️the GOBLET study: pelareorep+FFX+atezo in mPDAC, Abs 730; Post#H18
More than 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This is called a Ras G12 variant, and results in an overactive KRAS protein.
August 31, 2026 at 4:11 PM
More than 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This is called a Ras G12 variant, and results in an overactive KRAS protein.
#GI25 @ascocancer.bsky.social
Two trials on the tissue factor⛔️, pamrevlumab (PAM) in #PancreaticCancer, both by Dr. Piccozzi:
1⃣LAPIS, a R-Ph3 trial of chemo +/- PAM for LAPC, Oral Abstract #675
2⃣The Precision Promise trial @pancan.bsky.social of PAM+gem/nab-pac for mPDAC, Oral Abstract # 673
Two trials on the tissue factor⛔️, pamrevlumab (PAM) in #PancreaticCancer, both by Dr. Piccozzi:
1⃣LAPIS, a R-Ph3 trial of chemo +/- PAM for LAPC, Oral Abstract #675
2⃣The Precision Promise trial @pancan.bsky.social of PAM+gem/nab-pac for mPDAC, Oral Abstract # 673
January 11, 2025 at 6:54 PM
#GI25 @ascocancer.bsky.social
Two trials on the tissue factor⛔️, pamrevlumab (PAM) in #PancreaticCancer, both by Dr. Piccozzi:
1⃣LAPIS, a R-Ph3 trial of chemo +/- PAM for LAPC, Oral Abstract #675
2⃣The Precision Promise trial @pancan.bsky.social of PAM+gem/nab-pac for mPDAC, Oral Abstract # 673
Two trials on the tissue factor⛔️, pamrevlumab (PAM) in #PancreaticCancer, both by Dr. Piccozzi:
1⃣LAPIS, a R-Ph3 trial of chemo +/- PAM for LAPC, Oral Abstract #675
2⃣The Precision Promise trial @pancan.bsky.social of PAM+gem/nab-pac for mPDAC, Oral Abstract # 673
Kleine Erklärung zu dem Einsatz von Daraxonrasib beim metastasierten Pankreaskarzinom. Daraxonrasib ist (grob) ein RAS-Hemmer, RAS wiederum ein Proto-Onkogen, das im Pankreaskarzinom zu einem Onkogen mutiert.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | NEJM
Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, w...
www.nejm.org
June 1, 2026 at 7:57 PM
Kleine Erklärung zu dem Einsatz von Daraxonrasib beim metastasierten Pankreaskarzinom. Daraxonrasib ist (grob) ein RAS-Hemmer, RAS wiederum ein Proto-Onkogen, das im Pankreaskarzinom zu einem Onkogen mutiert.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Wow... "Among patients with (previously treated metastatic pancreatic ductal adenocarcinoma), treatment with daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy."
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | NEJM
Current therapies offer limited benefit for patients with previously treated metastatic
pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is
the key driver of PDAC, w...
www.nejm.org
June 7, 2026 at 5:02 AM
Wow... "Among patients with (previously treated metastatic pancreatic ductal adenocarcinoma), treatment with daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy."
Es La Noticia del año.
Aquí el estudio de FASE 3: www.nejm.org/doi/full/10....
Aquí el estudio de FASE 3: www.nejm.org/doi/full/10....
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | NEJM
Current therapies offer limited benefit for patients with previously treated metastatic
pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is
the key driver of PDAC, w...
www.nejm.org
June 1, 2026 at 6:31 AM
Es La Noticia del año.
Aquí el estudio de FASE 3: www.nejm.org/doi/full/10....
Aquí el estudio de FASE 3: www.nejm.org/doi/full/10....
The most common and aggressive form of pancreatic cancer is rarely detected early.
Metastatic pancreatic ductal adenocarcinoma (mPDAC) can be a scary diagnosis – and we remind the community that they are not alone.
Metastatic pancreatic ductal adenocarcinoma (mPDAC) can be a scary diagnosis – and we remind the community that they are not alone.
Pancreatic Cancer Awareness Month
This Pancreatic Cancer Awareness Month, PanCAN is inviting you to shine a light on pancreatic cancer. Let’s uplift survivors and those living with the disease, honor the lives we’ve lost and help ever...
pancan.org
November 24, 2025 at 6:47 PM
The most common and aggressive form of pancreatic cancer is rarely detected early.
Metastatic pancreatic ductal adenocarcinoma (mPDAC) can be a scary diagnosis – and we remind the community that they are not alone.
Metastatic pancreatic ductal adenocarcinoma (mPDAC) can be a scary diagnosis – and we remind the community that they are not alone.
Ohne Abo: Wirklich 60% mehr Überlebende, oder lediglich einige Monate mehr Lebenszeit?
„The median progression-free survival in the RAS G12 population was 7.3 months with daraxonrasib and 3.5 months with chemotherapy, and that in the overall population was 7.2 months and 3.6 months, respectively“
„The median progression-free survival in the RAS G12 population was 7.3 months with daraxonrasib and 3.5 months with chemotherapy, and that in the overall population was 7.2 months and 3.6 months, respectively“
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | NEJM
Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, w...
www.nejm.org
June 16, 2026 at 3:56 PM
Ohne Abo: Wirklich 60% mehr Überlebende, oder lediglich einige Monate mehr Lebenszeit?
„The median progression-free survival in the RAS G12 population was 7.3 months with daraxonrasib and 3.5 months with chemotherapy, and that in the overall population was 7.2 months and 3.6 months, respectively“
„The median progression-free survival in the RAS G12 population was 7.3 months with daraxonrasib and 3.5 months with chemotherapy, and that in the overall population was 7.2 months and 3.6 months, respectively“
#PreTest Q2⃣#TumorBoardTuesday Free #CME integrityce.com/TBT2024
🧐 Which of the following would you select for a 78-year-old man with mPDAC (CLDN18.2, 45%; MSS; gBRCA WT) and disease progression after gemcitabine/nab=pac❓
1) FOLFIRINOX
2) Regorafenib trial
3) CLDN18.2 BiTe trial
4) Pembrolizumab
🧐 Which of the following would you select for a 78-year-old man with mPDAC (CLDN18.2, 45%; MSS; gBRCA WT) and disease progression after gemcitabine/nab=pac❓
1) FOLFIRINOX
2) Regorafenib trial
3) CLDN18.2 BiTe trial
4) Pembrolizumab
February 4, 2025 at 2:35 PM
#PreTest Q2⃣#TumorBoardTuesday Free #CME integrityce.com/TBT2024
🧐 Which of the following would you select for a 78-year-old man with mPDAC (CLDN18.2, 45%; MSS; gBRCA WT) and disease progression after gemcitabine/nab=pac❓
1) FOLFIRINOX
2) Regorafenib trial
3) CLDN18.2 BiTe trial
4) Pembrolizumab
🧐 Which of the following would you select for a 78-year-old man with mPDAC (CLDN18.2, 45%; MSS; gBRCA WT) and disease progression after gemcitabine/nab=pac❓
1) FOLFIRINOX
2) Regorafenib trial
3) CLDN18.2 BiTe trial
4) Pembrolizumab
Nachschlag:
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | NEJM
Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, w...
www.nejm.org
August 27, 2026 at 10:33 PM
Nachschlag:
Second-line / Previously Treated Metastatic Pancreatic Cancer (mPDAC) from @mpishvaian.bsky.social:
myopenmedicine.com/algorithms/s...
myopenmedicine.com/algorithms/s...
Second-line / Previously Treated Metastatic Pancreatic Cancer (mPDAC)
The algorithm is broadly aligned with current practice for previously treated metastatic PDAC in emphasizing performance status assessment, clinical trial enrollment, molecular profiling, and use of e...
myopenmedicine.com
June 5, 2026 at 2:26 PM
Second-line / Previously Treated Metastatic Pancreatic Cancer (mPDAC) from @mpishvaian.bsky.social:
myopenmedicine.com/algorithms/s...
myopenmedicine.com/algorithms/s...
#PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 integrityce.com/TBT2024
🧐 Which of the following would you select for a 78-year-old man w/ mPDAC (CLDN18.2, 45%; MSS; gBRCA WT) and disease progression after gemcitabine/abraxane❓
1) FOLFIRINOX
2) Regorafenib trial
3) CLDN18.2 BiTe trial
4) Pembrolizumab
👉🏽 Free CME 🔗 integrityce.com/TBT2024
🧐 Which of the following would you select for a 78-year-old man w/ mPDAC (CLDN18.2, 45%; MSS; gBRCA WT) and disease progression after gemcitabine/abraxane❓
1) FOLFIRINOX
2) Regorafenib trial
3) CLDN18.2 BiTe trial
4) Pembrolizumab
February 5, 2025 at 2:06 AM
#PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 integrityce.com/TBT2024
🧐 Which of the following would you select for a 78-year-old man w/ mPDAC (CLDN18.2, 45%; MSS; gBRCA WT) and disease progression after gemcitabine/abraxane❓
1) FOLFIRINOX
2) Regorafenib trial
3) CLDN18.2 BiTe trial
4) Pembrolizumab
👉🏽 Free CME 🔗 integrityce.com/TBT2024
🧐 Which of the following would you select for a 78-year-old man w/ mPDAC (CLDN18.2, 45%; MSS; gBRCA WT) and disease progression after gemcitabine/abraxane❓
1) FOLFIRINOX
2) Regorafenib trial
3) CLDN18.2 BiTe trial
4) Pembrolizumab
TWINPEAK study: Spevatamig Plus Gemcitabine and Nab-Paclitaxel as 1L Therapy in CLDN18.2 Positive mPDAC
oncodaily.com/trial-update...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TWINPEAK
oncodaily.com/trial-update...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TWINPEAK
TWINPEAK study: Spevatamig Plus Gemcitabine and Nab-Paclitaxel as 1L Therapy in CLDN18.2 Positive mPDAC - OncoDaily
TWINPEAK study: Spevatamig Plus Gemcitabine and Nab-Paclitaxel as 1L Therapy in CLDN18.2 Positive mPDAC / ASCOGI2026, cancer, Headlines, metastatic pancreatic
oncodaily.com
January 11, 2026 at 12:58 AM
TWINPEAK study: Spevatamig Plus Gemcitabine and Nab-Paclitaxel as 1L Therapy in CLDN18.2 Positive mPDAC
oncodaily.com/trial-update...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TWINPEAK
oncodaily.com/trial-update...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TWINPEAK
Patients who experienced a clinical response to treatment showed evidence of immune activation within their tumors. This included increases in myeloid & T cells, which contributed to the antitumor response
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer.
2624Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) has a 5-year overall survival
(OS) rate of less than 5% and remains a leading cause of cancer related mortality.
Mitazalimab, a huma...
ascopubs.org
October 8, 2025 at 8:03 AM
Patients who experienced a clinical response to treatment showed evidence of immune activation within their tumors. This included increases in myeloid & T cells, which contributed to the antitumor response
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
